论文部分内容阅读
目的 观察培尼培南 /倍它米隆 (克倍宁 )对下呼吸道感染的有效性及安全性 ,并通过体外药敏试验比较三种常用碳青酶烯类的抗菌活性特点。方法 11例急性中 重度的细菌性下呼吸道感染病例 ,予克倍宁1 5 g/d,分 3次给药 ,疗程为 1～ 2周 ;同时对呼吸病房分离到的 91株革兰阴性菌进行体外药敏的比较。 结果 克倍宁的临床痊愈率为 2 7 3% ,有效率为 81% ,细菌清除率为 9% ,在治疗过程中未见不良反应发生 ;体外药敏检测提示克倍宁的抗菌活性与泰能和美平接近。结论 克倍宁在临床上对中 重度下呼吸道感染有良好效果 ,且不良反应较少
Objective To observe the efficacy and safety of penem-naive / betamembrane in the treatment of lower respiratory tract infections and to compare the antibacterial activity of three commonly used carbapenems in vitro susceptibility testing. Methods Eleven patients with acute moderate-severe bacterial lower respiratory tract infection were treated with 1 g / d of levofloxacin 15 mg once daily for 1 to 2 weeks. 91 Gram-negative bacteria isolated from respiratory ward In vitro susceptibility comparison. Results The clinical cure rate of Kepengning was 27.3%, the effective rate was 81% and the bacterial clearance rate was 9%. No adverse reactions occurred during the course of treatment. The antimicrobial activity of Kepengning in vitro was similar to that of Thai Can be close to the United States. Conclusions Keqinning has good clinical effect on moderate and severe lower respiratory tract infection with less adverse reactions